Skip to main content
. 2016 May 3;8:137–151. doi: 10.2147/CEOR.S104195

Table 1.

Summary of study characteristics of the included cost-effectiveness analyses assessing bortezomib or bortezomib-contained regimens for multiple myeloma

Included study Publication type Country Study design Model design Model cycle length Time horizon Cost perspective Annual discount rate for health benefits (%) Annual discount rate for costs (%) Model health state
Kouroukis et al12 Abstract Canada Cost-utility Markov Not reported 50 years Public health system 5 5 Progress free
Progressive disease
Death
Mucha et al13 Abstract Poland Cost-utility Markov Not reported Lifetime National Health Foundation 4 5 First-line
Second-line
Third-line
Subsequent line
Death
Van Beurden-Tan et al14 Abstract Germany Cost-effectiveness/utility Markov 1 month Lifetime Third payer 3 3 First-line
Second-line
Third-line
Fourth-line
Death
Rickert et al15 Abstract Sweden Cost-utility Partitioned survival model Not reported 30 years Public health system Not reported Not reported Progress free
Progressive disease
Death
Garrison et al16 Full publication USA Cost-effectiveness/utility Markov 1 month 20 years Third payer 3 3 Stable disease
Minor response
Partial response
Complete response
Treatment free
Progressive disease
Second-line
Death
Oster et al17 Abstract USA Cost-effectiveness/utility Partitioned survival model Not reported Lifetime Third payer 3 3 Progress free
Progressive disease
Death
Picot et al18 Full publication UK Cost-utility Partitioned survival model 6 weeks 30 years National health system 4 4 Treatment
Posttreatment
Progressive disease
Yoong et al19 Abstract Canada Cost-utility Not reported Not reported 10 years Public health system Not reported Not reported Not reported
Cavenagh et al20 Abstract USA Cost-effectiveness/utility Partitioned survival model Not reported Lifetime US payer 3 3 Not reported
Bagust et al21 Abstract UK Cost-utility Partitioned survival model Not reported Lifetime National health system 0 0 Not reported
Mehta et al22 Full publication USA Cost-utility Decision making tree Not reported Lifetime Third payer 0 0 Not reported
Felix et al23 Abstract Portugal Cost-effectiveness/utility Markov Not reported Lifetime Public health system 5 5 Not reported
Fragoulakis et al24 Full publication Greece Cost-effectiveness/utility Discrete event simulation Not reported Lifetime Public health system 4 4 Partial response
Complete response
Stable disease
Progressive disease
Hornberger et al25 Full publication Sweden Cost-effectiveness/utility Partitioned survival model 3 weeks 10 years Public health system 3 3 Progress free
Progressive diseas
Death
Jiang et al26 Abstract UK Cost-effectiveness/utility Partitioned survival model Not reported Lifetime National health system 4 4 Progressive free
Progressive disease
Death
Liwing et al27 Abstract Nordic four countries (Finland, Norway, Sweden, Denmark) Cost-effectiveness/utility Partitioned survival model Not reported Lifetime Public health system Not reported Not reported Progress free
Progressive disease
Death
Moller et al28 Full publication Norway Cost-effectiveness/utility Discrete event simulation Not reported 2 years Public health system 4 4 Partial response
Complete response
Stable disease
Progressive disease